Viatris Sustains Robust Dealmaking Appetite Following Successful Idorsia Partnership

1. Viatris, after completing a successful collaboration with Idorsia, maintains a strong interest in pursuing further deals to enhance its business portfolio.
2. The company is actively focusing on developing its core business and expanding in areas that contribute to patient impact and shareholder value.
3. Viatris reported positive financial results in the third quarter of 2023, indicating steady progress towards achieving its strategic objectives.
4. Viatris has completed several acquisitions, including those of Famy Life Sciences and Oyster Point Pharma, aiming to create a substantial presence in the eye care market.
5. The company anticipates reaching $1 billion in eye care sales by 2028 and has one of the largest commercial sales forces in ophthalmology in the United States.
6. Viatris received FDA approval for Ryzumvi, a treatment for pharmacologically-induced mydriasis, through its partnership with Ocuphire, bolstering its eye care offerings.
7. Despite the completion of certain planned divestitures, Viatris continues to express confidence in its ability to generate sustainable free cash flow and reinforce its balance sheet.